Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Five modifiable risk factors are associated with cardiovascular disease and death from any cause. Studies using individual-level data to evaluate the regional and sex-specific prevalence of the risk factors and their effect on these outcomes are lacking. METHODS: We pooled and harmonized individual-level data from 112 cohort studies conducted in 34 countries and 8 geographic regions participating in the Global Cardiovascular Risk Consortium. We examined associations between the risk factors (body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes) and incident cardiovascular disease and death from any cause using Cox regression analyses, stratified according to geographic region, age, and sex. Population-attributable fractions were estimated for the 10-year incidence of cardiovascular disease and 10-year all-cause mortality. RESULTS: Among 1,518,028 participants (54.1% of whom were women) with a median age of 54.4 years, regional variations in the prevalence of the five modifiable risk factors were noted. Incident cardiovascular disease occurred in 80,596 participants during a median follow-up of 7.3 years (maximum, 47.3), and 177,369 participants died during a median follow-up of 8.7 years (maximum, 47.6). For all five risk factors combined, the aggregate global population-attributable fraction of the 10-year incidence of cardiovascular disease was 57.2% (95% confidence interval [CI], 52.4 to 62.1) among women and 52.6% (95% CI, 49.0 to 56.1) among men, and the corresponding values for 10-year all-cause mortality were 22.2% (95% CI, 16.8 to 27.5) and 19.1% (95% CI, 14.6 to 23.6). CONCLUSIONS: Harmonized individual-level data from a global cohort showed that 57.2% and 52.6% of cases of incident cardiovascular disease among women and men, respectively, and 22.2% and 19.1% of deaths from any cause among women and men, respectively, may be attributable to five modifiable risk factors. (Funded by the German Center for Cardiovascular Research (DZHK); ClinicalTrials.gov number, NCT05466825.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“As well as the significant improvement in diabetic control, cardiometabolic risk was also improved by a significant reduction in SBP which was recorded across the cohort, specifically for those who had one or more co-existing medical conditions and for those who had a diagnosis of T2D of less than 6 years29.”
From mHealth low carbohydrate dietary intervention ameliorates glycaemic profile, blood pressure and weight status in people with type 2 diabetes (2025) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mice: Multivariate Imputation by Chained Equations in R
Buuren, S. V., & Groothuis-Oudshoorn, K. (2011) · Journal of Statistical Software · doi:10.18637/jss.v045.i03 · Cited by 13,870
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 1×
“Although very low non-HDL cholesterol concentrations are related to reduced CVD events, 25,26 some observations point towards higher all-cause mortality rates in individuals with very low levels at least in longer-term follow-up.”
(2010) · University of Twente Research Information · Cited by 6,037
Auditory and non-auditory effects of noise on health
Basner, M., Babisch, W., Davis, A., Brink, M., Clark, C., Janssen, S., & Stansfeld, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61613-x · Cited by 2,473 · cited 1×
“Environmental and exposomal factors such as physical activity 18 , alcohol consumption 28 , air pollution 29 , climate and noise 30 , educational level 3 or psychosocial risk factors including depression 31 impact CVD risk.”
Global burden of blood-pressure-related disease, 2001
Lawes, C. M., Hoorn, S. V., & Rodgers, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60655-8 · Cited by 2,330 · cited 3×
“While tobacco consumption is strongly associated with premature mortality, elevated blood pressure and cholesterol are more specifically related to CVD. 7 A tailored reduction in the burden of CVD and all-cause mortality for persons and populations can be achieved with better understanding of the region-and sex-specif…”
InfluentialEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“Although very low non-HDL cholesterol concentrations are related to reduced CVD events, 25,26 some observations point towards higher all-cause mortality rates in individuals with very low levels at least in longer-term follow-up.”
The Global Burden of Cardiovascular Diseases and Risk
Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V., & Roth, G. A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.005 · Cited by 2,217
Cited by
Items 201–300 of 980
Candelaria, D., Redfern, J., Zecchin, R. P., Brown, R., Freene, N., Fukumori, S., Gallagher, R. D., Gauci, S., Goodman, A., Hicks, D., et al. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.05.008 · Cited by 10
Sex‐associated differences in cardiac ageing: Clinical aspects and molecular mechanisms
Calvo-López, M., Ortega‐Paz, L., Jimenez‐Trinidad, F. R., Brugaletta, S., Sabaté, M., & Dantas, A. P. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14215 · Cited by 9
Sepehrinia, M., Pourmontaseri, H., Sayadi, M., Naghizadeh, M. M., Homayounfar, R., Farjam, M., Dehghan, A., & Alkamel, A. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200287 · Cited by 8
“A recent study revealed that more than 50 % 0f 10-year CVD incidence and nearly 20 % of CVD mortality were attributed to the five modifiable CVD risk factors including smoking, obesity, dyslipidemia, hypertension, and diabetes [4].”
BackgroundHigh LDL Particle and APOB Concentrations in Patients With Adrenal Cortical Adenomas
Sandooja, R., Saini, J., Kittithaworn, A., Garcia, R. G., Dogra, P., Atkinson, E. J., Yu, K., Fell, V. M., Simha, V., Connelly, M. A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae392 · Cited by 8
Influence of multiple risk factor control level on cardiovascular outcomes in hypertensive patients
Peng, X., Zhuang, M., Song, Q., Bai, J., & Cai, J. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae056 · Cited by 9
Chidumwa, G., Olivier, S., Ngubane, H., Zulu, T., Sithole, M., Gunda, R., The Vukuzazi Team, Sewpaul, R., Kruse, G. R., Rigotti, N. A., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-20791-4 · Cited by 8
Wierzbicki, A. S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2444986 · Cited by 10
Kim, J. H., Lee, Y., Nam, C. M., Kwon, Y., & Lee, J. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.103965 · Cited by 9
Kolivas, D., Fraser, L., Schweitzer, R., Brukner, P. D., & Moschonis, G. (2025) · Nutrients · doi:10.3390/nu17060937 · Cited by 10
Hu, Y., Dai, S., Zhao, L., & Zhao, L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1369343 · Cited by 8
Infection, inflammation, and cardiovascular risk: are we underestimating an old disease?
Arnold, N., & Köenig, W. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae104 · Cited by 8
Coca, A., Borghi, C., Stergiou, G. S., Khan, I., Koumas, A., Blacher, J., & Abdel-Moneim, M. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae048 · Cited by 12
Kolivas, D., Fraser, L., Schweitzer, R., Brukner, P., & Moschonis, G. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00053-6 · Cited by 7
2025 ACC/AHA Clinical Practice Guidelines Core Principles and Development Process
Otto, C. M., Abdullah, A. R., Davis, L. L., Ferrari, V. A., Fremes, S., Mukherjee, D., Prestera, L., & Ziaeian, B. (2026) · JACC · doi:10.1016/j.jacc.2025.06.013 · Cited by 7
Cardiovascular disease lipids and lipoproteins biomarker standardization
Lyle, A. N., Danilenko, U., Sugahara, O., & Vesper, H. W. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2462817 · Cited by 8
“Blood lipids, such as low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and total cholesterol (TC), are considered modifiable risk factors for cardiovascular diseases [2].”
Yang, L., Wang, Z., Zhao, S., Liu, M., Zhu, Y., Hu, F., Gao, X., & Wu, Y. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01655-6 · Cited by 9
Wang, Y., Sun, X., Zhang, X., Wang, X., Li, J., & Wang, K. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1653335 · Cited by 7
Wang, W., Liu, Y., Yuan, D., Yang, Y., Yang, Y., Ji, D., Pan, Y., Zhang, Y., Xu, J., Guo, H., et al. (2025) · Public Health · doi:10.1016/j.puhe.2025.106020 · Cited by 9
Yao, Y., Liu, N., Chen, S., Sun, M., & Guo, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03241-8 · Cited by 7
Debrah, O., Addo, F. O., Thomford, N. E., Zumesew, F., Debrah, A. A., Nsiah, P., Oduro-Boateng, I., Sadiq, N. U. A., Raji, A. S., -Atta, R. J. O., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05410-3 · Cited by 7
Arterial hypertension: the current state in Russia and worldwide. Review. Part I
Ismailova, M. A., Afanaseva, A. D., Garbuzova, E. V., & Ragino, Y. I. (2024) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2024-2389 · Cited by 7
Cui, H., Liu, Q., Zhao, Z., & Ma, X. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01433-6 · Cited by 7
Arterial hypertension—clinical trials update 2024
Tokcan, M., Lauder, L., Götzinger, F., Böhm, M., & Mahfoud, F. (2024) · Hypertension Research · doi:10.1038/s41440-024-01900-7 · Cited by 7
dos Santos, B. R., Casanova, G. K., Silva, T. R., Oppermann, K., & Spritzer, P. M. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0087 · Cited by 7
Peters, S. A., Wright, L. M., Yao, J. V., McCall, L., Thompson, T. N., Thompson, B. A., Johnson, R., Huynh, Q. L., Santiago, C. F., Trainer, A. H., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037311 · Cited by 7
Importance of Clinical, Laboratory, and Genetic Risk Factors for Incident CAD
Bhattacharya, R., Marnell, C. S., Cho, S. M. J., Patel, A. P., Ruan, Y., Koyama, S., Jowell, A. R., Trinder, M., Haidermota, S., Lannery, K., et al. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004937 · Cited by 8
Statins for the “SMuRFLess But Inflamed”
Ridker, P. M. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101318 · Cited by 14
Creighton, L., Caughers, G., Mitchell, G., McMahon, J., Neubeck, L., & Fitzsimons, D. (2025) · BMC Nursing · doi:10.1186/s12912-025-03611-x · Cited by 10
Yang, S., Yu, B., Liao, K., Qiao, X., Fan, Y., Li, M., Hu, Y., Chen, J., Ye, T., Cai, C., et al. (2024) · BMC Public Health · doi:10.1186/s12889-023-17073-w · Cited by 8
Solà, C., Viñals, C., Serés‐Noriega, T., Perea, V., Esmatjes, E., Boswell, L., Pané, A., Blanco-Carrasco, A. J., Vinagre, I., Mesa, A., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111771 · Cited by 7
Cardiovascular Risk in Prostate Cancer
Leong, D. P., Cirne, F., & Pinthus, J. H. (2024) · Cardiology Clinics · doi:10.1016/j.ccl.2024.09.003 · Cited by 8
Sastre-Alzamora, T., López, P. J. T., López‐González, Á. A., Vallejos, D., Paublini, H., & Ramírez‐Manent, J. I. (2024) · Diagnostics · doi:10.3390/diagnostics14212388 · Cited by 8
Ushering in a New Era of Hypertension Canada Guidelines: A Roadmap of What Lies Ahead
Goupil, R., Tsuyuki, R. T., Terenzi, K. A., Santesso, N. A., & Hundemer, G. L. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.10.020 · Cited by 7
Renal Denervation in Hypertension and Chronic Heart Failure
Lauder, L., Fisher, N. D. L., Böhm, M., Pfister, O., Secemsky, E. A., Taub, P. R., & Mahfoud, F. (2025) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2025.06.022 · Cited by 6
Gershon, G., Barr, J. R., Razavi, A. C., Yang, Y., Momin, E., Dzaye, O. D. A., Whelton, S. P., Blaha, M. J., Blumenthal, R. S., Sperling, L. S., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101301 · Cited by 6
Norha, J., Sjöros, T., Garthwaite, T., Laine, S., Laitinen, K., Houttu, N., Vähä‐Ypyä, H., Sievänen, H. T., Löyttyniemi, E., Vasankari, T. J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-20836-7 · Cited by 6
Santilli, F., Blaha, M. J., Ricci, F., & Simeone, P. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02966-4 · Cited by 9
CVD Mortality Disparities with Risk Factor Associations Across U.S. Counties
An, D. H. (2025) · Healthcare · doi:10.3390/healthcare13222937 · Cited by 6
“More than half of CVD cases may result from the combined impact of five major modifiable factors [5].”
InfluentialShao, Y., Li, Z., Wu, Q., Ye, L., & Shi, H. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07544-6 · Cited by 7
Chow, E. W. K., Fan, Y., Wu, H., Lau, E., Yang, A., Chow, E., Kong, A., Ronald, C. W., Chan, J. C. N., & Luk, A. O. Y. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03072-1 · Cited by 6
Web-based cardiovascular disease risk prediction using machine learning
Akhter, S., & Miller, J. H. (2026) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2026.1690664 · Cited by 6
A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases
Chechi, K., Chakaroun, R., Myridakis, A., Forslund, S. K., Fromentin, S., Nielsen, T., Aron‐Wisnewsky, J., Belda, E., Prifti, E., Lassen, P. B., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69405-0 · Cited by 6
Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation
Hendershot, C. S., Simmons, W. K., Jha, M. K., McKee, S. A., & Yammine, L. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.002 · Cited by 6
Erhöhter Blutdruck und Bluthochdruck: ESC-Leitlinie 2024 rückt Risikoreduktion in den Fokus
Schmieder, R. S., & Schunkert, H. (2024) · Herz · doi:10.1007/s00059-024-05285-8 · Cited by 7
Ding, Q., Xu, W., Chen, Y., Chang, S., & Zhang, J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1383470 · Cited by 7
Jung, S., Kim, H., Jung, Y., Shivakumar, M., Xiao, B., Kim, J., Jang, B., Yun, J., Won, H., Park, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56107-2 · Cited by 6
An, T., Han, H., Xie, J., Wang, Y., Zhao, Y., Jia, H., & Wang, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-13946-y · Cited by 6
Renal denervation is effective in reducing blood pressure in patients with CKD
Bosch, A., Kannenkeril, D., & Schmieder, R. E. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf126 · Cited by 6
John, A. S. S., Alagendran, S., Sivaprakasam, B., Ramaswamy, M. K. M., Selvaraj, K., Ramanathan, S., Chokkalingam, P. V., Ravindran, N., & Suvaiyarasan, S. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.363 · Cited by 9
Kelemen-Dagg, K., Wong, S., Emmerson, H., Coulton, R., Milne, R., Gauda, R., Opapeju, A., Swar, D., Large, A., Kolupanowicz, S., et al. (2025) · CJC Open · doi:10.1016/j.cjco.2025.07.002 · Cited by 7
Kubielas, G., Lee, C. S., Wleklik, M., Czapla, M., Surma, S., Jakubiak, G. K., Mysiak, A., Lisiak, M., & Uchmanowicz, I. (2025) · BMC Public Health · doi:10.1186/s12889-025-24385-6 · Cited by 6
“Modifiable factors—includ-ing excess weight, hypertension, non-HDL cholesterol, smoking, and diabetes—contribute substantially to the burden of CVD, accounting for a large proportion of incident cases and related mortality [17].”
Córdoba‐Melo, B. D., Seni-Molina, S., Arango-Ibañez, J. P., Ayala, M. R., Méndez, J., Quintero-Yepes, V., Mejía-Cadavid, L. A., Cruz-Cuevas, J. D., Ordoñez, N. A., Buitrago, A. F., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02657-9 · Cited by 6
Five easy pieces only account for a fraction of incident cardiovascular disease and all-cause deaths
Liuzzo, G., & Patrono, C. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad731 · Cited by 6
Hematopoietic Stem Cells as an Integrative Hub Linking Lifestyle to Cardiovascular Health
Chen, X., Liu, C., Wang, J., & Du, C. (2024) · Cells · doi:10.3390/cells13080712 · Cited by 7
“…body mass index, tobacco smoking, low-density lipoprotein cholesterol level, and diabetes, most of which are closely associated with lifestyle, have been consistently linked to enhanced cardiovascular risk [4], underscoring the pivotal implications of lifestyle in CVD pathogenesis and management.”
BackgroundLin, C., Hsu, T., Tung, Y., Hsiao, F., Chou, S., Lin, Y., Chen, S., & Chu, P. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033780 · Cited by 9
Lazutkina, A. Y. (2024) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20240525 · Cited by 6
Zarei, M., Sarmadi, S., Boozaripour, M., & Sanaie, N. (2025) · BMC Nursing · doi:10.1186/s12912-025-02909-0 · Cited by 6
Li, M., Zhao, S., Yu, S., Maimaitiaili, R., Xu, Y., Yan, L., Zhao, Y., & Zhang, Y. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101350 · Cited by 6
Mulder, J. W. C. M., Galema‐Boers, A. M. H., Kranenburg, L. W., Redekop, K., & van Lennep, J. E. R. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119101 · Cited by 5
Association between sleep duration and hypertension risk in patients with obstructive sleep apnea
Wang, Y., Chen, X., Lu, F., Yan, Y. R., Li, S. Q., Zhang, L., Lin, Y. N., & Li, Q. Y. (2025) · npj Primary Care Respiratory Medicine · doi:10.1038/s41533-025-00429-7 · Cited by 6
Cheng, J. S.-C., Thorndike, A. N., & Yi, S. S. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037997 · Cited by 5
Wu, J., Chang, H.-Y., Kao, C., Hung, K.-C., Yu, T., & Lin, Y. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120390 · Cited by 5
Tu, D., Zuo, X., Li, P., & Wang, J. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1612693 · Cited by 5
Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region
Agboyibor, M. K., Nambiema, A., Gbeasor, F. D., Barengo, N. C., Okeibunor, J., Jouven, X., Dangou, J.-M., Farzadfar, F., & Empana, J. P. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.3377 · Cited by 5
Sud, M. K., Chaudhry, A., Qui, F., Haldenby, O., Godoy, L. C., Austin, P. C., Roifman, I., Manuel, D. G., Eurich, D. T., Wijeysundera, H. C., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102108 · Cited by 5
Al-Jarshawi, M. H. A., Galimzhanov, A. M., Zimarino, M., Elgendy, I. Y., Diaz‐Arocutipa, C., Kobo, O. M., & Mamas, M. A. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.041645 · Cited by 5
Sun, S., Zhou, C., Sun, G., & Lian, Z. (2025) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2025.102020 · Cited by 6
Improving Blood Pressure Management and Control With Out-of-Office Blood Pressure Monitoring
Nugent, J. T., Binka, E., & Brady, T. M. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf222 · Cited by 6
Perezalonso-Espinosa, J., Ramírez‐García, D., Díaz-Sánchez, J. P., Carrillo-Herrera, K. B., Cabrera-Quintana, L. A., Dávila-López, G., Fermín‐Martínez, C. A., Liceaga, A. M., Basile‐Alvarez, M. R., Berumen-Campos, J., et al. (2026) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2026.101403 · Cited by 5
“29,30 33 Nonetheless, most CVD risk models have been developed using data from high-income countries, largely due to greater data availability.”
Effect of Baduanjin on Blood Pressure Among Individuals With High-Normal Blood Pressure
Pu, B., Zhang, L., Sun, Y. Z., Yu, Y., Yan, L., Li, Y., Liu, J., Zheng, X., Zhang, H., Peng, Y., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.01.014 · Cited by 6
Hyperthermia applications in cardiovascular and cancer therapy treatments
Imanlou, S., & Kambiz Vafai, B. (2024) · Advances in heat transfer · doi:10.1016/bs.aiht.2024.02.002 · Cited by 5
Pharmacologic Treatment of Hypertension in Older Adults
Todd, O. M., Knight, M., Jacobs, J. A., Derington, C. G., Sheppard, J. P., & Bress, A. P. (2024) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2024.04.004 · Cited by 5
Liu, Z., Yan, M., Tse, L. A., Zhu, Y., Lang, X., Liu, X., Lin, Y., & Hu, B. (2024) · Journal of Epidemiology and Global Health · doi:10.1007/s44197-024-00251-3 · Cited by 7
H19 lncRNA triggers ferroptosis, exacerbating ox-LDL-induced artery endothelial cell damage in vitro
Tang, F. R., Tian, L., Zhu, X., Yang, S., Zeng, H., & Yang, Y. (2024) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-242261 · Cited by 5
Vajdi, M., Gataa, I. S., Tabrizi, F. P. F., Nikrad, N., Hojati, A., Darzi, M., Noshadi, N., Khajeh, M., Farhangi, M. A., & Alipour, B. (2024) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2024.106879 · Cited by 5
Wang, X., Li, F., Chen, S., Chen, S., Zhu, S., Zhang, Y., Reiter, R. J., Ashrafizadeh, M., Lin, J., Wang, G., et al. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111292 · Cited by 5
An Interpretable Approach with Explainable AI for the Detection of Cardiovascular Disease
Sapra, V., & Sapra, L. (2024) · International Conference on Integrated Intelligence and Communication Systems (ICIICS) · doi:10.1109/iciics63763.2024.10860265 · Cited by 5
Temporelli, P. L. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae086 · Cited by 5
A Hybrid Approach for Cardiovascular Disease Risk Evaluation
Sesadri, U., Jumlesha, S., Raju, S. H., Adinarayna, S., Choudhury, N., & Jadala, V. C. (2025) · International Conference on Mobile Computing and Sustainable Informatics (ICMCSI) · doi:10.1109/icmcsi64620.2025.10883543 · Cited by 5
Low carbohydrate high fat-diet in real life; A descriptive analysis of cardiovascular risk factors
Hagström, H., Hagfors, L. N., Hedelin, R., Brunström, M., & Lindmark, K. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200384 · Cited by 6
“When measuring effect on surrogate markers such as risk factors for cardiovascular disease, one must also consider that the attributable effect of the five most common modifiable risk factors on cardiovascular disease is not close to 100 percent but rather 50 – 60 % [49].”
Irannejad, K., Krishnan, S., Iskander, B., Kambalapalli, S., Punnanithinont, N., Ichikawa, K., Lakshmanan, S., & Budoff, M. J. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01089-z · Cited by 5
Pullback pressure gradient: A paradigm shift in physiology-guided revascularization
Kechichian, A., Mizukami, T., Malhotra, G., Spratt, J., Ikeda, K., Corradetti, S., Munhoz, D., Sakai, K., Sonck, J., Wyffels, E., et al. (2025) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2025.04.035 · Cited by 5
Driendl, S., Baumert, M., Arzt, M. E., Stark, K. J., Pěč, J., Sinha, F., Kmiec, L., Zeman, F., & Stadler, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf259 · Cited by 5
Navigating the value proposition of artificial intelligence in cardiovascular disease prevention
Shah, A. (2025) · Digital Health · doi:10.1177/20552076251357409 · Cited by 6
Zhang, S., Chen, L., & Wang, Y. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110034 · Cited by 5
Palomo‐Piñón, S., Alcocer, L. A., Álvarez‐López, H., Cardona-Muñóz, E. G., Chávez‐Mendoza, A., Díaz‐Díaz, E., Enciso‐Muñoz, J. M., Galván‐Oseguera, H., Rosas-Peralta, M., Cortes, L. R. G., et al. (2025) · Journal of Clinical Hypertension · doi:10.1111/jch.70106 · Cited by 6
Ler, P., Jylhävä, J., Hägg, S., Finkel, D., Aslan, A. K. D., Ploner, A., & Karlsson, I. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105883 · Cited by 5
Quiet flames: inflammation without traditional risk factors
Arnold, N., & Köenig, W. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf653 · Cited by 5
Li, J., Lin, S., Pei, H., Xie, G., Pei, L., & Chen, G. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04260 · Cited by 6
Changes in Acute Coronary Syndrome Clinic after the Devastating Earthquake in Türkiye
Akkuş, O. (2024) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2024.4207 · Cited by 5
Obesogenic Medication Use in End‐Stage Kidney Disease and Association With Transplant Listing
Orandi, B. J., Li, Y., Seckin, T., Bae, S., Lonze, B. E., Ren‐Fielding, C. J., Lofton, H. F., Gujral, A., Segev, D. L., & McAdams‐DeMarco, M. (2024) · Clinical Transplantation · doi:10.1111/ctr.15414 · Cited by 4
Unraveling the Complex Cellular Repair Mechanisms Following Myocardial Infarction
Chen, R., Fu, Y., Hu, L., Chen, Y., & Li, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136002 · Cited by 5
The Role of Polygenic Risk Score in the General Population: Current Status and Future Prospects
Takase, M., & Hozawa, A. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22039 · Cited by 4
Antithrombotic potential of lornoxicam and possible mechanistic pathways
Khalid, W., Khan, A., & Ali, F. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103681 · Cited by 5
Maxwell, J. W. C., Ripoll‐Rozada, J., Mackay, A. S., Alwis, I. D., Ford, D., Trought, C. B. J., Santos, J. A., Smythe, R. E., Liu, J. S. T., Zuccolotto, Z., et al. (2025) · Chemical Science · doi:10.1039/d5sc04734j · Cited by 5
Cardioprotective role of RBFox1 in myocardial infarction-induced heart failure
He, M., Tay, W. T., Song, N., Liu, T., Ren, S. V., Zhu, C., Onubogu, N., Biler, O., Tan, J. E., Keezer, C., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf206 · Cited by 5
Guo, J., Koutrakis, P., Vieira, C. L. Z., Fan, Y., Wang, Y., Lian, X., Wang, Z., Tang, Z., Huang, S., & Li, J. (2025) · Nature Communications · doi:10.1038/s41467-025-65963-x · Cited by 5
Suárez-Villadat, B., Montero, M., Montero, S., López-García, A., & Villagra, A. (2025) · Healthcare · doi:10.3390/healthcare14010081 · Cited by 4
“The reduction in central adiposity observed in our study is clinically relevant because abdominal obesity is strongly associated with metabolic and cardiovascular risk factors in adolescents with DS [7,8].”
Brieger, D. G., Gray, M. P., Fathieh, S., Magnussen, C., & Figtree, G. A. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120638 · Cited by 5
Imani, M., Maroosi, A., Shojaei, S., Heidari, K., Hoseinzadeh, S. M., Daneshi, N., Saber, Z., Sajadi, N. A., & Mohammadzadeh, M. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100719 · Cited by 6
Metadata
- Authors
- The Global Cardiovascular Risk Consortium
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Corresponding author
- The Global Cardiovascular Risk Consortium
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-10-05
- Volume
- 389
- Issue
- 14
- Pages
- 1273-1285
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10589462
- OpenAlex
- W4386194106
- Cited by
- 909
- References
- 35
- Citations by year
- 2026: 285 · 2025: 359 · 2024: 242 · 2023: 23
- FWCI
- 47.54
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- Research Portal (Queen's University Belfast) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion, cc-by)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Duo Research Archive (University of Oslo) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Funders
- European Union AFFECT-EU (Horizon 2020, No. 847770)
- German Center for Cardiovascular Research (not applicable)
- European Union MORGAM (Biomed, BMH4-CT98-3183)
- European Union GenomEUtwin (FP5, QLG2-CT-2002-01254)
- European Union ENGAGE (FP7, HEALTH-F4-2007-201413)
- European Union CHANCES (FP7, HEALTH-F3-2010-242244)
- European Union BiomarCaRE (FP7, HEALTH-F2-2011-278913)
- European Union euCanSHare (Horizon 2020, No. 825903)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- modifiable risk factors, cardiovascular disease, all-cause mortality, population attributable fraction, body mass index, systolic blood pressure, non-HDL cholesterol, smoking, diabetes mellitus, sex differences, regional variation, global cardiovascular risk, cohort studies, cardiovascular disease incidence, women's health
- MeSH terms
- Heart Disease Risk Factors, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Male, Middle Aged, Risk Factors, Smoking, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.